NO781300L - Fremgangsmaate for fremstilling av fysiologisk aktive guanidinderivater - Google Patents
Fremgangsmaate for fremstilling av fysiologisk aktive guanidinderivaterInfo
- Publication number
- NO781300L NO781300L NO781300A NO781300A NO781300L NO 781300 L NO781300 L NO 781300L NO 781300 A NO781300 A NO 781300A NO 781300 A NO781300 A NO 781300A NO 781300 L NO781300 L NO 781300L
- Authority
- NO
- Norway
- Prior art keywords
- radical
- formula
- compound
- carbon atoms
- atom
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 36
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 128
- 150000003254 radicals Chemical class 0.000 claims description 104
- -1 sulfinyl radical Chemical class 0.000 claims description 90
- 125000004432 carbon atom Chemical group C* 0.000 claims description 56
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 239000007858 starting material Substances 0.000 claims description 26
- 125000004434 sulfur atom Chemical group 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 18
- 150000002357 guanidines Chemical class 0.000 claims description 18
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 239000012458 free base Substances 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- QWJNFFYFEKXZBF-UHFFFAOYSA-N cyanocyanamide Chemical compound N#CNC#N QWJNFFYFEKXZBF-UHFFFAOYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 150000005840 aryl radicals Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 249
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 165
- 239000000243 solution Substances 0.000 description 98
- 239000000203 mixture Substances 0.000 description 90
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 63
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- 239000000047 product Substances 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000010992 reflux Methods 0.000 description 26
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Natural products NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000000725 suspension Substances 0.000 description 20
- 229910021529 ammonia Inorganic materials 0.000 description 19
- 239000003085 diluting agent Substances 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 241000786363 Rhampholeon spectrum Species 0.000 description 13
- 229960001340 histamine Drugs 0.000 description 13
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 13
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- BGPJLYIFDLICMR-UHFFFAOYSA-N 1,4,2,3-dioxadithiolan-5-one Chemical compound O=C1OSSO1 BGPJLYIFDLICMR-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YDDXVAXDYKBWDX-UHFFFAOYSA-N 1-cyano-3-[2-[[2-(diaminomethylideneamino)-4-thiazolyl]methylthio]ethyl]-2-methylguanidine Chemical compound N#CNC(=NC)NCCSCC1=CSC(N=C(N)N)=N1 YDDXVAXDYKBWDX-UHFFFAOYSA-N 0.000 description 8
- SLKRPKDOFFHSCW-UHFFFAOYSA-N 2-[4-(4-aminobutyl)-1,3-thiazol-2-yl]guanidine Chemical compound NCCCCC1=CSC(NC(N)=N)=N1 SLKRPKDOFFHSCW-UHFFFAOYSA-N 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 238000012746 preparative thin layer chromatography Methods 0.000 description 8
- ALUADPCVKGLEJH-UHFFFAOYSA-N 2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethylazanium;chloride Chemical compound Cl.NCCSCC1=CSC(NC(N)=N)=N1 ALUADPCVKGLEJH-UHFFFAOYSA-N 0.000 description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 7
- 239000011976 maleic acid Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- ORECNKBJIMKZNX-UHFFFAOYSA-N 1,3-thiazol-3-ium;chloride Chemical compound Cl.C1=CSC=N1 ORECNKBJIMKZNX-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- OKGXJRGLYVRVNE-UHFFFAOYSA-N diaminomethylidenethiourea Chemical compound NC(N)=NC(N)=S OKGXJRGLYVRVNE-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- BSRYQVAYLHEYGO-UHFFFAOYSA-N methyl n-cyano-n'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]carbamimidothioate Chemical compound N#CN=C(SC)NCCSCC1=CSC(NC(N)=N)=N1 BSRYQVAYLHEYGO-UHFFFAOYSA-N 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000000580 secretagogue effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 4
- SZJMLHRRRVLTQD-UHFFFAOYSA-N 2-(6-bromo-5-oxohexyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCC(=O)CBr)C(=O)C2=C1 SZJMLHRRRVLTQD-UHFFFAOYSA-N 0.000 description 4
- IQUVPEBKMIEVMZ-UHFFFAOYSA-N 2-[4-(4-aminobutyl)-1,3-thiazol-2-yl]guanidine;hydrobromide;hydrochloride Chemical compound Cl.Br.NCCCCC1=CSC(NC(N)=N)=N1 IQUVPEBKMIEVMZ-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 206010016717 Fistula Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 4
- 229960001380 cimetidine Drugs 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000003890 fistula Effects 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 230000027119 gastric acid secretion Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 3
- SGUWJWKVYWTNKK-UHFFFAOYSA-N 1-[4-(2-aminoethylsulfanylmethyl)-1,3-thiazol-2-yl]-2-butylguanidine;hydrochloride Chemical compound Cl.CCCCN=C(N)NC1=NC(CSCCN)=CS1 SGUWJWKVYWTNKK-UHFFFAOYSA-N 0.000 description 3
- FLWLEGXUGDILNI-UHFFFAOYSA-N 1-[4-[4-(1,3-dioxoisoindol-2-yl)butyl]-1,3-thiazol-2-yl]-2-methylguanidine;hydrobromide Chemical compound Br.S1C(NC(N)=NC)=NC(CCCCN2C(C3=CC=CC=C3C2=O)=O)=C1 FLWLEGXUGDILNI-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- FPPHUAGSEOFMQM-UHFFFAOYSA-N 2-[4-(4-aminobutyl)-5-bromo-1,3-thiazol-2-yl]guanidine Chemical compound NCCCCC=1N=C(NC(N)=N)SC=1Br FPPHUAGSEOFMQM-UHFFFAOYSA-N 0.000 description 3
- POHBHKPFQKGZOE-UHFFFAOYSA-N 2-[5-(4-aminobutyl)-1h-imidazol-2-yl]guanidine Chemical compound NCCCCC1=CNC(NC(N)=N)=N1 POHBHKPFQKGZOE-UHFFFAOYSA-N 0.000 description 3
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000400611 Eucalyptus deanei Species 0.000 description 3
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HPXWWLGOFMSKHV-UHFFFAOYSA-N [4-(chloromethyl)-1,3-thiazol-2-yl]-(diaminomethylidene)azanium;chloride Chemical compound Cl.NC(N)=NC1=NC(CCl)=CS1 HPXWWLGOFMSKHV-UHFFFAOYSA-N 0.000 description 3
- 230000009858 acid secretion Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 3
- 229960000582 mepyramine Drugs 0.000 description 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 3
- LYGJFVRRKHAVQX-UHFFFAOYSA-N methyl N-cyano-N'-[5-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]pentyl]carbamimidothioate Chemical compound N#CN=C(SC)NCCCCCC1=CSC(NC(N)=N)=N1 LYGJFVRRKHAVQX-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- BMKHXSAWSRRBDY-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-3-methylthiourea Chemical compound OC(=O)\C=C/C(O)=O.CNC(=S)NCCSCC1=CSC(NC(N)=N)=N1 BMKHXSAWSRRBDY-BTJKTKAUSA-N 0.000 description 2
- CCJBZSBTJMHAQM-UHFFFAOYSA-N 1-cyano-2-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-3-ethylguanidine Chemical compound CCNC(=NC#N)NCCSCC1=CSC(NC(N)=N)=N1 CCJBZSBTJMHAQM-UHFFFAOYSA-N 0.000 description 2
- FFIOBYJPVAXSLA-UHFFFAOYSA-N 1-cyano-2-methyl-3-[4-[2-[(n'-methylcarbamimidoyl)amino]-1,3-thiazol-4-yl]butyl]guanidine Chemical compound N#CN=C(NC)NCCCCC1=CSC(NC(N)=NC)=N1 FFIOBYJPVAXSLA-UHFFFAOYSA-N 0.000 description 2
- OEHXWSVQONDPNL-UHFFFAOYSA-N 1-cyano-3-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfinyl]ethyl]-2-methylguanidine Chemical compound N#CN=C(NC)NCCS(=O)CC1=CSC(NC(N)=N)=N1 OEHXWSVQONDPNL-UHFFFAOYSA-N 0.000 description 2
- QYXHFICHKVRPSH-UHFFFAOYSA-N 1-cyano-3-[4-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]butyl]-2-methylguanidine Chemical compound N#CN=C(NC)NCCCCC1=CSC(NC(N)=N)=N1 QYXHFICHKVRPSH-UHFFFAOYSA-N 0.000 description 2
- NJADCURUOHUHPU-UHFFFAOYSA-N 2-(8-bromo-7-oxooctyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCCC(=O)CBr)C(=O)C2=C1 NJADCURUOHUHPU-UHFFFAOYSA-N 0.000 description 2
- JXNJORJFKUCUSM-UHFFFAOYSA-N 2-[4-(2-aminoethylsulfanylmethyl)-1,3-thiazol-2-yl]guanidine;dihydrochloride Chemical compound Cl.Cl.NCCSCC1=CSC(NC(N)=N)=N1 JXNJORJFKUCUSM-UHFFFAOYSA-N 0.000 description 2
- JNHFQOCQRKPRPV-UHFFFAOYSA-N 2-[4-(3-aminopropylsulfanylmethyl)-1,3-thiazol-2-yl]guanidine;hydrochloride Chemical compound Cl.NCCCSCC1=CSC(NC(N)=N)=N1 JNHFQOCQRKPRPV-UHFFFAOYSA-N 0.000 description 2
- HAPNOYHWHGAHBH-UHFFFAOYSA-N 2-[4-(6-aminohexyl)-1,3-thiazol-2-yl]guanidine;dihydrochloride Chemical compound Cl.Cl.NCCCCCCC1=CSC(NC(N)=N)=N1 HAPNOYHWHGAHBH-UHFFFAOYSA-N 0.000 description 2
- HKTIMFCVQVQNQN-UHFFFAOYSA-N 2-[4-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]butyl]-1-nitroguanidine Chemical compound NC(=N)NC1=NC(CCCCNC(N)=N[N+]([O-])=O)=CS1 HKTIMFCVQVQNQN-UHFFFAOYSA-N 0.000 description 2
- MTTWINGFPPFHBJ-UHFFFAOYSA-N 2-[4-[4-(1,3-dioxoisoindol-2-yl)butyl]-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.S1C(NC(=N)N)=NC(CCCCN2C(C3=CC=CC=C3C2=O)=O)=C1 MTTWINGFPPFHBJ-UHFFFAOYSA-N 0.000 description 2
- XWZHSIPQBVBJQR-UHFFFAOYSA-N 2-[4-[4-[(2-methoxy-3,4-dioxocyclobuten-1-yl)amino]butyl]-1,3-thiazol-2-yl]guanidine Chemical compound O=C1C(=O)C(OC)=C1NCCCCC1=CSC(NC(N)=N)=N1 XWZHSIPQBVBJQR-UHFFFAOYSA-N 0.000 description 2
- NGKCAVITQWUKDI-UHFFFAOYSA-N 2-[5-[4-(1,3-dioxoisoindol-2-yl)butyl]-1h-imidazol-2-yl]guanidine Chemical compound N1C(NC(=N)N)=NC(CCCCN2C(C3=CC=CC=C3C2=O)=O)=C1 NGKCAVITQWUKDI-UHFFFAOYSA-N 0.000 description 2
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 2
- ZNHPMMBWZHUBNX-UHFFFAOYSA-N 2-butyl-1-[4-(chloromethyl)-1,3-thiazol-2-yl]guanidine;hydrochloride Chemical compound Cl.CCCCN=C(N)NC1=NC(CCl)=CS1 ZNHPMMBWZHUBNX-UHFFFAOYSA-N 0.000 description 2
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
- KIPFPUCUWBTAQK-UHFFFAOYSA-N 7-(1,3-dioxoisoindol-2-yl)heptanoic acid Chemical compound C1=CC=C2C(=O)N(CCCCCCC(=O)O)C(=O)C2=C1 KIPFPUCUWBTAQK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010065713 Gastric Fistula Diseases 0.000 description 2
- 108010079943 Pentagastrin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- WLXALCKAKGDNAT-UHFFFAOYSA-N diazoethane Chemical compound CC=[N+]=[N-] WLXALCKAKGDNAT-UHFFFAOYSA-N 0.000 description 2
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- FCESNXQFXNYCIS-UHFFFAOYSA-N methyl N-cyano-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]carbamimidate Chemical compound N#CN=C(OC)NCCSCC1=CSC(NC(N)=N)=N1 FCESNXQFXNYCIS-UHFFFAOYSA-N 0.000 description 2
- RRNFEWMTOUNYAU-UHFFFAOYSA-N methyl N-cyano-N'-[4-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]butyl]carbamimidothioate Chemical compound N#CN=C(SC)NCCCCC1=CSC(NC(N)=N)=N1 RRNFEWMTOUNYAU-UHFFFAOYSA-N 0.000 description 2
- NMUDHNUSDYPLNH-UHFFFAOYSA-N methyl N-cyano-N'-[4-[2-[(N'-methylcarbamimidoyl)amino]-1,3-thiazol-4-yl]butyl]carbamimidothioate Chemical compound N#CN=C(SC)NCCCCC1=CSC(NC(N)=NC)=N1 NMUDHNUSDYPLNH-UHFFFAOYSA-N 0.000 description 2
- FLZZNZJENFNFOJ-UHFFFAOYSA-N methyl n'-nitrocarbamimidothioate Chemical compound CSC(N)=N[N+]([O-])=O FLZZNZJENFNFOJ-UHFFFAOYSA-N 0.000 description 2
- XYXPDAUAWISERG-UHFFFAOYSA-N n-[(e)-n'-[4-[2-[(n-cyano-n'-methylcarbamimidoyl)amino]ethylsulfanylmethyl]-1,3-thiazol-2-yl]carbamimidoyl]acetamide Chemical compound N#CNC(=NC)NCCSCC1=CSC(\N=C(/N)NC(C)=O)=N1 XYXPDAUAWISERG-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 2
- 229960000444 pentagastrin Drugs 0.000 description 2
- LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 description 2
- 125000005544 phthalimido group Chemical group 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- NWZYKHSNRMAZLI-UHFFFAOYSA-N (n'-butylcarbamimidoyl)thiourea Chemical compound CCCCNC(=N)NC(N)=S NWZYKHSNRMAZLI-UHFFFAOYSA-N 0.000 description 1
- KFZQSRZJDFEUID-UHFFFAOYSA-N (n'-methylcarbamimidoyl)thiourea Chemical compound CNC(=N)NC(N)=S KFZQSRZJDFEUID-UHFFFAOYSA-N 0.000 description 1
- DGASFFDEJUOHIV-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-2-methyl-3-(4-methylphenyl)sulfonylguanidine Chemical compound OC(=O)\C=C/C(O)=O.C=1C=C(C)C=CC=1S(=O)(=O)N=C(NC)NCCSCC1=CSC(NC(N)=N)=N1 DGASFFDEJUOHIV-BTJKTKAUSA-N 0.000 description 1
- AHVWJQAKDMSCMD-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyano-2-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-3-propan-2-ylguanidine Chemical compound OC(=O)\C=C/C(O)=O.CC(C)NC(=NC#N)NCCSCC1=CSC(NC(N)=N)=N1 AHVWJQAKDMSCMD-BTJKTKAUSA-N 0.000 description 1
- ASXNVLMLBVSWSU-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyano-2-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]guanidine Chemical compound OC(=O)\C=C/C(O)=O.NC(=N)NC1=NC(CSCCNC(N)=NC#N)=CS1 ASXNVLMLBVSWSU-BTJKTKAUSA-N 0.000 description 1
- NGOALGCZRJXZPW-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyano-3-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-2-(2-methoxyethyl)guanidine Chemical compound OC(=O)\C=C/C(O)=O.COCCN=C(NC#N)NCCSCC1=CSC(N=C(N)N)=N1 NGOALGCZRJXZPW-BTJKTKAUSA-N 0.000 description 1
- IAQWQPFOYUZLEH-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyano-3-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-2-methylguanidine Chemical compound OC(=O)\C=C/C(O)=O.N#CN=C(NC)NCCSCC1=CSC(NC(N)=N)=N1 IAQWQPFOYUZLEH-BTJKTKAUSA-N 0.000 description 1
- RBADEFJWUDVTKX-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyano-3-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfinyl]ethyl]-2-methylguanidine Chemical compound OC(=O)\C=C/C(O)=O.N#CN=C(NC)NCCS(=O)CC1=CSC(NC(N)=N)=N1 RBADEFJWUDVTKX-BTJKTKAUSA-N 0.000 description 1
- LEOXHYFOKVKXPD-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyano-3-[3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]propyl]-2-methylguanidine Chemical compound OC(=O)\C=C/C(O)=O.N#CN=C(NC)NCCCSCC1=CSC(NC(N)=N)=N1 LEOXHYFOKVKXPD-BTJKTKAUSA-N 0.000 description 1
- DDWJIRRWQWHRAF-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-cyano-3-cyclohexyl-2-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]guanidine Chemical compound OC(=O)\C=C/C(O)=O.S1C(NC(=N)N)=NC(CSCCNC(NC2CCCCC2)=NC#N)=C1 DDWJIRRWQWHRAF-BTJKTKAUSA-N 0.000 description 1
- KCWCYIBNGKOFSQ-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-nitroguanidine Chemical compound OC(=O)\C=C/C(O)=O.NC(=N)NC1=NC(CSCCNC(N)=N[N+]([O-])=O)=CS1 KCWCYIBNGKOFSQ-BTJKTKAUSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- NXGHEDHQXXXTTP-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-2-nitroethene Chemical group CSC(SC)=C[N+]([O-])=O NXGHEDHQXXXTTP-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- OMLLSCMJUUNCGG-UHFFFAOYSA-N 1-[2-[[2-[(n'-butylcarbamimidoyl)amino]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-3-methylthiourea Chemical compound CCCCN=C(N)NC1=NC(CSCCNC(=S)NC)=CS1 OMLLSCMJUUNCGG-UHFFFAOYSA-N 0.000 description 1
- AZOKERXGLDXYMI-UHFFFAOYSA-N 1-[4-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]butyl]-3-methylthiourea Chemical compound CNC(=S)NCCCCC1=CSC(NC(N)=N)=N1 AZOKERXGLDXYMI-UHFFFAOYSA-N 0.000 description 1
- NJGNZHKEGDVRST-UHFFFAOYSA-N 1-[4-[2-(diaminomethylideneamino)-1h-imidazol-5-yl]butyl]-3-methylthiourea Chemical compound CNC(=S)NCCCCC1=CNC(NC(N)=N)=N1 NJGNZHKEGDVRST-UHFFFAOYSA-N 0.000 description 1
- VCDVKQBSAFRHSQ-UHFFFAOYSA-N 1-[6-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]hexyl]-3-methylthiourea Chemical compound CNC(=S)NCCCCCCC1=CSC(NC(N)=N)=N1 VCDVKQBSAFRHSQ-UHFFFAOYSA-N 0.000 description 1
- NYAMPFDYTBDISG-UHFFFAOYSA-N 1-chloro-3-(triphenyl-$l^{5}-phosphanylidene)propan-2-one Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)CCl)C1=CC=CC=C1 NYAMPFDYTBDISG-UHFFFAOYSA-N 0.000 description 1
- YQGGBYGVWLCRKS-UHFFFAOYSA-N 1-cyano-2-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]guanidine Chemical compound NC(=N)NC1=NC(CSCCNC(N)=NC#N)=CS1 YQGGBYGVWLCRKS-UHFFFAOYSA-N 0.000 description 1
- UWVYNQAXOGATNJ-UHFFFAOYSA-N 1-cyano-2-[4-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]butyl]guanidine Chemical compound NC(=N)NC1=NC(CCCCNC(N)=NC#N)=CS1 UWVYNQAXOGATNJ-UHFFFAOYSA-N 0.000 description 1
- FFUPIIYGULDCEY-UHFFFAOYSA-N 1-cyano-3-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-2-(2-hydroxyethyl)guanidine Chemical compound NC(N)=NC1=NC(CSCCNC(NC#N)=NCCO)=CS1 FFUPIIYGULDCEY-UHFFFAOYSA-N 0.000 description 1
- OMBGFJQURQOFSF-UHFFFAOYSA-N 1-cyano-3-[5-[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]pentyl]-2-methylguanidine Chemical compound N#CN=C(NC)NCCCCCC1=CSC(NC(N)=N)=N1 OMBGFJQURQOFSF-UHFFFAOYSA-N 0.000 description 1
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical class NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- LMRDBJZQDUVCQH-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetaldehyde Chemical compound C1=CC=C2C(=O)N(CC=O)C(=O)C2=C1 LMRDBJZQDUVCQH-UHFFFAOYSA-N 0.000 description 1
- ZDMJVZQTAJYNPF-UHFFFAOYSA-N 2-(6-chloro-5-oxoheptyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCC(=O)C(Cl)C)C(=O)C2=C1 ZDMJVZQTAJYNPF-UHFFFAOYSA-N 0.000 description 1
- VUJFSLQYHOZBAC-UHFFFAOYSA-N 2-(7-chloro-6-oxooctyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCC(=O)C(Cl)C)C(=O)C2=C1 VUJFSLQYHOZBAC-UHFFFAOYSA-N 0.000 description 1
- FGOADZSSHWIZHR-UHFFFAOYSA-N 2-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-nitroguanidine Chemical compound NC(=N)NC1=NC(CSCCNC(N)=N[N+]([O-])=O)=CS1 FGOADZSSHWIZHR-UHFFFAOYSA-N 0.000 description 1
- JFINSZHXZPNADJ-UHFFFAOYSA-N 2-[4-(2-aminoethylsulfanylmethyl)-1,3-thiazol-2-yl]guanidine Chemical compound NCCSCC1=CSC(NC(N)=N)=N1 JFINSZHXZPNADJ-UHFFFAOYSA-N 0.000 description 1
- NNHNQKHCRUPZFR-UHFFFAOYSA-N 2-[4-(4-aminobutyl)-5-methyl-1,3-thiazol-2-yl]guanidine;dihydrochloride Chemical compound Cl.Cl.CC=1SC(NC(N)=N)=NC=1CCCCN NNHNQKHCRUPZFR-UHFFFAOYSA-N 0.000 description 1
- KOIJRZKRAFSQDV-UHFFFAOYSA-N 2-[4-(5-aminopentyl)-1,3-thiazol-2-yl]guanidine;hydrobromide;hydrochloride Chemical compound Cl.Br.NCCCCCC1=CSC(NC(N)=N)=N1 KOIJRZKRAFSQDV-UHFFFAOYSA-N 0.000 description 1
- BNJNKQKMZVNLIO-UHFFFAOYSA-N 2-[4-(6-aminohexyl)-1,3-thiazol-2-yl]guanidine Chemical compound NCCCCCCC1=CSC(NC(N)=N)=N1 BNJNKQKMZVNLIO-UHFFFAOYSA-N 0.000 description 1
- HZMURLJYNYVFMN-UHFFFAOYSA-N 2-[4-[4-[[1-(methylamino)-2-nitroethenyl]amino]butyl]-1,3-thiazol-2-yl]guanidine Chemical group [O-][N+](=O)C=C(NC)NCCCCC1=CSC(NC(N)=N)=N1 HZMURLJYNYVFMN-UHFFFAOYSA-N 0.000 description 1
- KVSOUEFNHIYNTP-UHFFFAOYSA-N 2-[4-[4-[[2,2-dicyano-1-(methylamino)ethenyl]amino]butyl]-1,3-thiazol-2-yl]guanidine Chemical group N#CC(C#N)=C(NC)NCCCCC1=CSC(N=C(N)N)=N1 KVSOUEFNHIYNTP-UHFFFAOYSA-N 0.000 description 1
- VQTZKGCXTCXYMY-UHFFFAOYSA-N 2-[4-[4-[[2-(methylamino)-3,4-dioxocyclobuten-1-yl]amino]butyl]-1,3-thiazol-2-yl]guanidine Chemical compound O=C1C(=O)C(NC)=C1NCCCCC1=CSC(NC(N)=N)=N1 VQTZKGCXTCXYMY-UHFFFAOYSA-N 0.000 description 1
- QSCMDILXJWPESH-UHFFFAOYSA-N 2-[4-[6-(1,3-dioxoisoindol-2-yl)hexyl]-1,3-thiazol-2-yl]guanidine Chemical compound S1C(NC(=N)N)=NC(CCCCCCN2C(C3=CC=CC=C3C2=O)=O)=C1 QSCMDILXJWPESH-UHFFFAOYSA-N 0.000 description 1
- VZUZDAIQHGMDBE-UHFFFAOYSA-N 2-[4-[6-(1,3-dioxoisoindol-2-yl)hexyl]-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.S1C(NC(=N)N)=NC(CCCCCCN2C(C3=CC=CC=C3C2=O)=O)=C1 VZUZDAIQHGMDBE-UHFFFAOYSA-N 0.000 description 1
- DQJLKSMNSNUNPD-UHFFFAOYSA-N 2-[methylamino(methylsulfanyl)methylidene]propanedinitrile Chemical group CNC(SC)=C(C#N)C#N DQJLKSMNSNUNPD-UHFFFAOYSA-N 0.000 description 1
- SYZKAFCPWNFONG-UHFFFAOYSA-N 2-chloro-4-fluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1Cl SYZKAFCPWNFONG-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SZBNZTGCAMLMJY-UHFFFAOYSA-N 3,4-dimethoxycyclobut-3-ene-1,2-dione Chemical compound COC1=C(OC)C(=O)C1=O SZBNZTGCAMLMJY-UHFFFAOYSA-N 0.000 description 1
- IBSDSIHTMABATG-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)propanal Chemical compound C1=CC=C2C(=O)N(CCC=O)C(=O)C2=C1 IBSDSIHTMABATG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- GMEDUXHKSSWXSL-UHFFFAOYSA-N 3-sulfanylpropylazanium;chloride Chemical compound Cl.NCCCS GMEDUXHKSSWXSL-UHFFFAOYSA-N 0.000 description 1
- YCMJYLOOFMIYGD-UHFFFAOYSA-N 5-(1,3-dioxoisoindol-2-yl)pentanoyl chloride Chemical compound C1=CC=C2C(=O)N(CCCCC(=O)Cl)C(=O)C2=C1 YCMJYLOOFMIYGD-UHFFFAOYSA-N 0.000 description 1
- KOQCISGPATVUJH-UHFFFAOYSA-N 6-(1,3-dioxoisoindol-2-yl)hexanoyl chloride Chemical compound C1=CC=C2C(=O)N(CCCCCC(=O)Cl)C(=O)C2=C1 KOQCISGPATVUJH-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- ZGEKHRWSHKCOEZ-UHFFFAOYSA-N N#CN=C(OC)NCCCCC1=CSC(NC(N)=N)=N1 Chemical compound N#CN=C(OC)NCCCCC1=CSC(NC(N)=N)=N1 ZGEKHRWSHKCOEZ-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- QAMKBWKDOFJUKY-BTJKTKAUSA-N OC(=O)\C=C/C(O)=O.CNC(=O)NCCSCC1=CSC(NC(N)=N)=N1 Chemical compound OC(=O)\C=C/C(O)=O.CNC(=O)NCCSCC1=CSC(NC(N)=N)=N1 QAMKBWKDOFJUKY-BTJKTKAUSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940043315 aluminum hydroxide / magnesium hydroxide Drugs 0.000 description 1
- SXSTVPXRZQQBKQ-UHFFFAOYSA-M aluminum;magnesium;hydroxide;hydrate Chemical compound O.[OH-].[Mg].[Al] SXSTVPXRZQQBKQ-UHFFFAOYSA-M 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000530 carbenoxolone Drugs 0.000 description 1
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- ZOKYZTUQSVAKHS-UHFFFAOYSA-N dimethoxymethylidenecyanamide Chemical compound COC(OC)=NC#N ZOKYZTUQSVAKHS-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- XQNWXMUBPCOAEG-UHFFFAOYSA-N ethyl N-cyano-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]carbamimidate Chemical compound CCOC(=NC#N)NCCSCC1=CSC(NC(N)=N)=N1 XQNWXMUBPCOAEG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- MMBDAJMDNVQFDV-UHFFFAOYSA-N methyl n-[amino(methylsulfanyl)methylidene]carbamate Chemical compound COC(=O)N=C(N)SC MMBDAJMDNVQFDV-UHFFFAOYSA-N 0.000 description 1
- HCBPHBQMSDVIPZ-UHFFFAOYSA-N methylcyclohexatriene Chemical compound CC1=CC=C=C[CH]1 HCBPHBQMSDVIPZ-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- NGNTXFAQLVPNLA-UHFFFAOYSA-N n-[(e)-n'-[4-[2-[(n-cyano-n'-methylcarbamimidoyl)amino]ethylsulfanylmethyl]-1,3-thiazol-2-yl]carbamimidoyl]propanamide Chemical compound CCC(=O)N\C(N)=N\C1=NC(CSCCNC(NC#N)=NC)=CS1 NGNTXFAQLVPNLA-UHFFFAOYSA-N 0.000 description 1
- CGIDZVQTMPIEEE-UHFFFAOYSA-N n-[n'-[4-[2-[(n-cyano-n'-methylcarbamimidoyl)amino]ethylsulfanylmethyl]-1,3-thiazol-2-yl]carbamimidoyl]benzamide Chemical compound N#CNC(=NC)NCCSCC1=CSC(\N=C(\N)NC(=O)C=2C=CC=CC=2)=N1 CGIDZVQTMPIEEE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1638977 | 1977-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO781300L true NO781300L (no) | 1978-10-23 |
Family
ID=10076448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO781300A NO781300L (no) | 1977-04-20 | 1978-04-13 | Fremgangsmaate for fremstilling av fysiologisk aktive guanidinderivater |
Country Status (28)
Country | Link |
---|---|
US (4) | US4165377A (da) |
JP (3) | JPS53147069A (da) |
AR (1) | AR223315A1 (da) |
AT (1) | AT363099B (da) |
AU (1) | AU516297B2 (da) |
BE (1) | BE866156A (da) |
CA (1) | CA1097658A (da) |
CS (2) | CS200546B2 (da) |
DD (1) | DD135824A5 (da) |
DK (1) | DK172778A (da) |
ES (3) | ES468985A1 (da) |
FI (1) | FI781230A (da) |
FR (2) | FR2387970A1 (da) |
GB (1) | GB2060607B (da) |
GR (1) | GR62452B (da) |
HU (1) | HU176807B (da) |
IE (1) | IE47044B1 (da) |
IL (1) | IL54549A0 (da) |
IN (1) | IN148903B (da) |
IT (1) | IT1094469B (da) |
NL (1) | NL190486C (da) |
NO (1) | NO781300L (da) |
NZ (1) | NZ186965A (da) |
PL (2) | PL113054B1 (da) |
PT (1) | PT67921B (da) |
SE (1) | SE7804461L (da) |
SU (1) | SU730299A3 (da) |
ZA (1) | ZA782129B (da) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL49528A (en) * | 1975-05-21 | 1980-11-30 | Smith Kline French Lab | Imidazolyl(or thiazolyl)methylthio(or butyl)guanidine or thiourea derivatives,their preparation and pharmaceutical compositions comprising them |
DE2961923D1 (en) * | 1978-01-18 | 1982-03-11 | Ici Plc | Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them |
DE2963363D1 (en) * | 1978-05-24 | 1982-09-09 | Ici Plc | Antisecretory thiadiazole derivatives, processes for their manufacture and pharmaceutical compositions containing them |
US4200578A (en) | 1978-12-18 | 1980-04-29 | Bristol-Myers Company | Thiazole derivatives |
DE3069889D1 (en) * | 1979-01-18 | 1985-02-14 | Ici Plc | Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them |
US4521418A (en) * | 1979-02-21 | 1985-06-04 | Smith Kline & French Laboratories Limited | Guanidinothiazolyl derivatives |
PH16099A (en) * | 1979-03-06 | 1983-06-24 | Yamanouchi Pharma Co Ltd | Guanidinothiazole compounds,process for preparing them and medical composition containing them |
JPS6056143B2 (ja) * | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
CH644369A5 (de) * | 1979-05-03 | 1984-07-31 | Sandoz Ag | 2-amino-4-chlorthiazolverbindungen. |
US4242351A (en) * | 1979-05-07 | 1980-12-30 | Imperial Chemical Industries Limited | Antisecretory oxadiazoles and pharmaceutical compositions containing them |
DK160611C (da) * | 1979-09-04 | 1991-09-16 | Bristol Myers Squibb Co | Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider |
US4359466A (en) * | 1979-10-24 | 1982-11-16 | Smith Kline & French Laboratories Limited | Guanidine compounds |
IL61234A (en) * | 1979-10-24 | 1984-03-30 | Smith Kline French Lab | Guanidino thiazolyl alkylamino(alkylthioalkylamino)nitrotetrahydropyridines,process for preparing them and pharmaceutical compositions containing them |
GR71929B (da) * | 1979-11-13 | 1983-08-19 | Ici Ltd | |
NZ196923A (en) * | 1980-04-29 | 1983-12-16 | Shionogi & Co | 2-guanidino-4-(-acylaminoalkyl(thio)methyl)thiazoles and analogs |
EP0045155B1 (en) * | 1980-07-30 | 1985-01-02 | Imperial Chemical Industries Plc | Guanidine derivatives |
EP0057227A1 (fr) * | 1980-08-11 | 1982-08-11 | Société de Recherches et de Synthèses Organiques SA | Imino-alkyle et amino-nitrile cyano-guanidines |
US4904792A (en) * | 1980-10-02 | 1990-02-27 | Eli Lilly And Company | N-thiazolymethylthioalkyl-N'-alkylamidines and related compounds |
US4760075A (en) * | 1980-10-02 | 1988-07-26 | Eli Lilly And Company | N-thiazolylmethylthioalkyl-N-alkyl-amidines and related compounds |
US4374843A (en) * | 1980-10-14 | 1983-02-22 | Pfizer Inc. | 2-Guanidino-4-heteroarylthiazoles |
DE3270716D1 (en) * | 1981-02-27 | 1986-05-28 | Ici Plc | Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity |
CA1233818A (en) * | 1981-03-09 | 1988-03-08 | David J. Gilman | Guanidine derivatives as histamine h-2 receptor antagonists |
CA1209998A (en) * | 1981-03-09 | 1986-08-19 | David J. Gilman | Amide derivatives as histamine h-2 receptor antagonists |
US4460584A (en) * | 1981-03-13 | 1984-07-17 | Imperial Chemical Industries Plc | Nitrogen heterocycles |
IN158869B (da) * | 1981-03-18 | 1987-02-07 | Ici Plc | |
EP0065823A1 (en) * | 1981-05-13 | 1982-12-01 | Imperial Chemical Industries Plc | Heterocyclic guanidines as histamine H-2 antagonists |
DE3267110D1 (de) * | 1981-05-18 | 1985-12-05 | Ici Plc | Amidine derivatives |
US4510313A (en) * | 1981-08-20 | 1985-04-09 | Pfizer Inc. | 2-Guanidino-4-heteroarylthiazoles |
US4590299A (en) * | 1981-08-20 | 1986-05-20 | Pfizer Inc. | 2-guanidino-4-heteroarylthiazoles |
US4452987A (en) * | 1981-08-20 | 1984-06-05 | Pfizer Inc. | Haloacetyl imidazoles |
JPS5872571A (ja) * | 1981-10-27 | 1983-04-30 | Shionogi & Co Ltd | 2−グアニジノ−4−〔2−(ホルムアミド)エチルチオメチル〕チアゾ−ルの製法 |
US4647557A (en) * | 1982-12-28 | 1987-03-03 | Gerard Moinet | Novel heterocyclic derivatives bearing an amino radical, processes for their production and the pharmaceutical compositions containing them |
JPS59227870A (ja) * | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | 新規2−グアニジノチアゾリン誘導体ならびにその製造法 |
JPS60255756A (ja) * | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
JPS6160673A (ja) * | 1984-08-30 | 1986-03-28 | Yamanouchi Pharmaceut Co Ltd | グアニジノチアゾ−ル誘導体の製造法 |
US4814341A (en) * | 1986-08-26 | 1989-03-21 | Reiter Lawrence A | 2-guanidino-4-(2-furyl) thiazoles as antiulcer agents |
WO1988003141A1 (en) * | 1986-10-29 | 1988-05-05 | Pfizer Inc. | Processes for 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and analogs |
US5837716A (en) * | 1995-11-13 | 1998-11-17 | Albany Medical College | Analgesic heterocyclic compounds |
WO1998040367A1 (en) * | 1997-03-11 | 1998-09-17 | Albemarle Corporation | Novel thiazole derivatives and their preparation |
US5731442A (en) * | 1997-03-11 | 1998-03-24 | Albemarle Corporation | Synthesis of thiazole derivatives |
US5856500A (en) * | 1997-03-11 | 1999-01-05 | Albemarle Corporation | Synthesis of thiazole derivatives |
US9745274B2 (en) | 2013-07-03 | 2017-08-29 | Shin Nippon Biomedical Laboratories, Ltd. | Compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor |
WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1305547A (da) | 1969-10-29 | 1973-02-07 | ||
GB1305549A (da) | 1969-10-29 | 1973-02-07 | ||
GB1305548A (da) | 1969-10-29 | 1973-02-07 | ||
BE758145A (fr) | 1969-10-29 | 1971-04-28 | Smith Kline French Lab | Iso-thio-urees et derives |
BE758146A (fr) | 1969-10-29 | 1971-04-28 | Smith Kline French Lab | Derives de l'amidine |
GB1305550A (da) | 1969-10-29 | 1973-02-07 | ||
GB1341375A (en) | 1969-11-19 | 1973-12-19 | Smith Kline French Lab | Aminoalkylimidazoles and process for their production |
GB1341376A (en) | 1969-11-19 | 1973-12-19 | Smith Kline French Lab | Pharmaceutical compositions comprising 4-methyl-5-2-aminoethyl imidazole |
CA946968A (en) | 1970-05-18 | 1974-05-07 | Xerox Corporation | System for generating laser light of the three primary colors |
GB1307539A (en) | 1970-06-25 | 1973-02-21 | Smith Kline French Lab | Thiourea derivatives |
GB1336061A (en) | 1971-02-03 | 1973-11-07 | Ilford Ltd | Photographic emulsions |
US3905984A (en) * | 1971-03-09 | 1975-09-16 | Smith Kline French Lab | Pyridyl substituted thioalkyl-and oxyalkyl-thioureas and ureas |
US3932427A (en) * | 1971-03-09 | 1976-01-13 | Smith Kline & French Laboratories, Inc. | Pyridyl substituted aminoalkyl-thioureas and ureas |
US4018928A (en) * | 1971-03-09 | 1977-04-19 | Smith Kline & French Laboratories Limited | Pyridyl substituted aminoalkyl-thioureas and ureas |
US3950353A (en) * | 1971-03-09 | 1976-04-13 | Smith Kline & French Laboratories Limited | Pharmacologically active thiourea and urea compounds |
US4018931A (en) * | 1971-03-09 | 1977-04-19 | Smith Kline & French Laboratories Limited | Pharmacologically active thiourea and urea compounds |
GB1395929A (en) | 1972-08-08 | 1975-05-29 | Smith Kline French Lab | Thioureas |
US4049672A (en) * | 1971-03-09 | 1977-09-20 | Smith Kline & French Laboratories Limited | 4-Methyl-5-imidazolylmethylthioethylamine and -S-methylisothiourea |
US4053473A (en) * | 1971-07-22 | 1977-10-11 | Smith Kline & French Laboratories Limited | Pharmacologically active thiourea and urea compounds |
GB1338169A (en) | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
GB1399283A (en) | 1972-04-20 | 1975-07-02 | Smith Kline French Lab | Pharmaceutical compositions |
GB1400319A (en) | 1972-04-20 | 1975-07-16 | Smith Kline French Lab | Pharmaceutical compositions |
US3975530A (en) * | 1972-09-05 | 1976-08-17 | Smith Kline & French Laboratories Limited | N-cyano-N'-heterocyclic-alkyl quanidine inhibitors of H2 histamine receptors |
US3920822A (en) * | 1972-09-05 | 1975-11-18 | Smith Kline French Lab | Inhibition of histamine activity with cyanoguanidines |
GB1397436A (en) * | 1972-09-05 | 1975-06-11 | Smith Kline French Lab | Heterocyclic n-cyanoguinidines |
GB1398426A (en) | 1972-09-05 | 1975-06-18 | Smith Kline French Lab | Heterocyclic substituted guanidines |
GB1421999A (en) | 1973-02-08 | 1976-01-21 | Smith Kline French Lab | Heterocyclic containing sulphoxides |
GB1419994A (en) | 1973-05-03 | 1976-01-07 | Smith Kline French Lab | Heterocyclicalkylaminotheterocyclic compounds methods for their preparation and compositions comprising them |
GB1421792A (en) | 1973-05-17 | 1976-01-21 | Smith Kline French Lab | Heterocyclic substituted-1, 1-diamino-ethylene derivatives methods for their preparation and compositions containing them |
GB1422408A (en) | 1973-06-12 | 1976-01-28 | Smith Kline French Lab | Imidazo 1,2-a pyridines |
GB1431589A (en) | 1973-07-13 | 1976-04-07 | Smith Kline French Lab | Ureas, thioureas and guanidines n,n-disubstituted by heterocyclo- alkylene and/or heterocycloalkylenethioalkylene groups |
GB1565205A (en) | 1975-07-31 | 1980-04-16 | Smith Kline French Lab | Heterocyclic sulphoxides |
GB1493931A (en) | 1974-02-07 | 1977-11-30 | Smith Kline French Lab | Guanidines isothioureas and thioureas |
GB1496787A (en) | 1974-03-12 | 1978-01-05 | Smith Kline French Lab | Heteroalkylthioalkyl amidine derivatives |
CA1004576A (en) * | 1974-05-24 | 1977-02-01 | Ralph O. Jacobsen | Bale shredder |
GB1497260A (en) | 1974-06-28 | 1978-01-05 | Smith Kline French Lab | Guanidine derivatives |
GB1530895A (en) | 1974-09-02 | 1978-11-01 | Smith Kline French Lab | Electrochemical reduction of 4-imidazole carboxylic acids |
GB1533379A (en) | 1974-09-02 | 1978-11-22 | Smith Kline French Lab | Process for the preparation of heterocyclic substituted ureas |
GB1533380A (en) | 1974-09-02 | 1978-11-22 | Smith Kline French Lab | Process for the preparation of heterocyclic substituted thioureas and h-cyanoguanidines |
GB1531221A (en) | 1974-09-02 | 1978-11-08 | Smith Kline French Lab | Process for preparing guanidine derivatives |
GB1533378A (en) | 1974-09-02 | 1978-11-22 | Smith Kline French Lab | Process for the preparation of heterocyclic substituted thioureas |
GB1531231A (en) | 1974-09-02 | 1978-11-08 | Smith Kline French Lab | Process for the production of cyanoguanidine derivatives |
GB1542840A (en) | 1975-02-03 | 1979-03-28 | Smith Kline French Lab | Heterocyclic dithiocarbamates and isothioureas |
GB1554153A (en) | 1975-05-15 | 1979-10-17 | Smith Kline French Lab | Process for making 2-amino-2-alkylthionitroethylenes |
GB1563090A (en) * | 1975-07-31 | 1980-03-19 | Smith Kline French Lab | Cyclobutene-diones |
FR2317591B1 (fr) | 1975-07-08 | 1979-06-15 | Clarel | Appareil d'eclairage pour lampes fluorescentes |
GB1565647A (en) | 1975-07-31 | 1980-04-23 | Smith Kline French Lab | Pharmacologically active compounds 4-substituted-imidazole-5-methanols |
GB1564502A (en) | 1975-07-31 | 1980-04-10 | Smith Kline French Lab | Guanidines thioureas and 1,1-diamino-2-nitroethylene derivatives |
IN146736B (da) | 1975-10-02 | 1979-08-25 | Smith Kline French Lab | |
US4099672A (en) * | 1977-02-28 | 1978-07-11 | Ray Albert Sheahan | Shower-head fixture |
US4309435A (en) * | 1978-10-16 | 1982-01-05 | Imperial Chemical Industries Ltd. | Antisecretory guanidine derivatives and pharmaceutical compositions containing them |
JPS6056143B2 (ja) * | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
-
1978
- 1978-04-13 NO NO781300A patent/NO781300L/no unknown
- 1978-04-13 ZA ZA00782129A patent/ZA782129B/xx unknown
- 1978-04-13 IE IE728/78A patent/IE47044B1/en not_active IP Right Cessation
- 1978-04-13 NZ NZ186965A patent/NZ186965A/xx unknown
- 1978-04-13 GR GR55969A patent/GR62452B/el unknown
- 1978-04-14 AU AU35106/78A patent/AU516297B2/en not_active Expired
- 1978-04-15 IN IN274/DEL/78A patent/IN148903B/en unknown
- 1978-04-17 CA CA301,263A patent/CA1097658A/en not_active Expired
- 1978-04-18 PL PL1978218009A patent/PL113054B1/pl unknown
- 1978-04-18 PL PL1978206191A patent/PL113082B1/pl unknown
- 1978-04-19 NL NLAANVRAGE7804159,A patent/NL190486C/xx not_active IP Right Cessation
- 1978-04-19 US US05/897,910 patent/US4165377A/en not_active Expired - Lifetime
- 1978-04-19 CS CS788113A patent/CS200546B2/cs unknown
- 1978-04-19 PT PT67921A patent/PT67921B/pt unknown
- 1978-04-19 FR FR7811536A patent/FR2387970A1/fr active Granted
- 1978-04-19 AT AT0276978A patent/AT363099B/de not_active IP Right Cessation
- 1978-04-19 SE SE7804461A patent/SE7804461L/xx unknown
- 1978-04-19 IL IL54549A patent/IL54549A0/xx not_active IP Right Cessation
- 1978-04-19 BE BE186933A patent/BE866156A/xx not_active IP Right Cessation
- 1978-04-19 DD DD78204901A patent/DD135824A5/xx unknown
- 1978-04-19 CS CS782521A patent/CS200545B2/cs unknown
- 1978-04-20 FI FI781230A patent/FI781230A/fi not_active Application Discontinuation
- 1978-04-20 AR AR271843A patent/AR223315A1/es active
- 1978-04-20 HU HU78IE834A patent/HU176807B/hu unknown
- 1978-04-20 DK DK172778A patent/DK172778A/da active IP Right Grant
- 1978-04-20 IT IT22558/78A patent/IT1094469B/it active
- 1978-04-20 SU SU782607390A patent/SU730299A3/ru active
- 1978-04-20 JP JP4713678A patent/JPS53147069A/ja active Granted
- 1978-04-20 ES ES468985A patent/ES468985A1/es not_active Expired
- 1978-06-22 GB GB8006269A patent/GB2060607B/en not_active Expired
- 1978-11-08 ES ES474929A patent/ES474929A1/es not_active Expired
-
1979
- 1979-02-01 ES ES477387A patent/ES477387A1/es not_active Expired
- 1979-08-13 US US06/065,801 patent/US4234735A/en not_active Expired - Lifetime
- 1979-08-13 US US06/065,802 patent/US4262126A/en not_active Expired - Lifetime
-
1980
- 1980-07-25 US US06/172,302 patent/US4347370A/en not_active Expired - Lifetime
-
1982
- 1982-06-16 FR FR8210491A patent/FR2519341A1/fr active Granted
-
1983
- 1983-11-18 JP JP58216401A patent/JPS59130276A/ja active Granted
- 1983-11-18 JP JP58216402A patent/JPS59130277A/ja active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO781300L (no) | Fremgangsmaate for fremstilling av fysiologisk aktive guanidinderivater | |
US4165378A (en) | Guanidine derivatives of imidazoles and thiazoles | |
EP0003640B1 (en) | Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them | |
US4342765A (en) | Guanidine derivatives and pharmaceutical compositions containing them | |
EP0006679B1 (en) | Antisecretory thiadiazole derivatives, processes for their manufacture and pharmaceutical compositions containing them | |
US4493840A (en) | Antisecretory guanidine derivatives, and pharmaceutical compositions containing them | |
US4242351A (en) | Antisecretory oxadiazoles and pharmaceutical compositions containing them | |
EP0059597A2 (en) | Guanidino-substituted heterocyclic derivatives having histamine H-2 antagonist activity | |
EP0010893B1 (en) | Antisecretory branched-chain heterocyclic guanidine derivatives, processes for their manufacture, intermediates, and pharmaceutical compositions containing said derivatives | |
EP0045155B1 (en) | Guanidine derivatives | |
US4338448A (en) | 3-Chloroalkyl-5-guanidino-1,2,4-oxadiazoles | |
US4696933A (en) | Guanidine compounds useful as histamine H2-antagonists | |
KR810000599B1 (ko) | 헤테로사이클 유도체의 제법 | |
KR810000600B1 (ko) | 헤테로 사이클 유도체의 제법 | |
CS241000B2 (en) | Production method of heterocyclic guanidine derivatives | |
IE47045B1 (en) | Guanidine derivatives |